Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Lipid Luminations

Emerging LDL Therapies

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.

    One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on?  What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.

     

    Brought to you by:

    NLA logo

     

Recommended
Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.

    One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on?  What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.

     

    Brought to you by:

    NLA logo

     

Schedule15 Jan 2025